Nanobiotechnology for the prevention of dialysis-related amyloidosis.

Dialysis-related amyloidosis is related to the inefficient removal of beta(2)-microglobulin (beta(2)-m) that is mainly responsible for the formation of amyloid fibrils deposited on the joints and in the heart, blood vessels and digestive system. Magnetically assisted hemodialysis (MAHD) can be used for the prevention of dialysis-related amyloidosis. MAHD is based on ferromagnetic nanoparticle-targeted binding substance conjugates (FN-TBS Cs) that should be administered to the patient before the dialysis session.

Utilization of nanobiotechnology in haemodialysis: mock-dialysis experiments on homocysteine.

Background: The utilization of modern achievements from nanobiotechnology has resulted in novel modalities for renal replacement therapy. For conventional intermittent haemodialysis (HD), sophisticated membranes are currently being manufactured that guarantee selective removal of target toxins. These membranes have a narrow pore-size distribution that is focused around a mean value at the nanometre level.

Selenium metabolism in patients on continuous ambulatory peritoneal dialysis.

Background: Selenium is an essential trace element for living organisms. In many publications, researchers express concern about a possible Se deficiency in patients with end-stage chronic renal failure (ESCRF) undergoing continuous ambulatory peritoneal dialysis (CAPD). However, in a number of published articles, the data provide no evidence that patients under CAPD develop Se deficiency.